

RECEIVED

MAR 26 2003


TECH CENTER 1600/2900

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/994466
(use as many sheets as necessary)				Filing Date	November 26, 2001
				First Named Inventor	Ragupathy Madiyalakan
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	AREX-P03-002

U. S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					T ⁶

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
SJH	AW	Price, M.R. and Tendler, S.J.B. Polymorphic epithelial mucins (PEM): molecular characteristics and association with breast cancer. Breast 2, 3-7 (1993).			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>[Signature]</i>	Date Considered	4/30/04
--------------------	--------------------	-----------------	---------

RECEIVED
Sheets Page 1 of 1

Form PTO/SB/08 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(several sheets if necessary)</i>		Docket Number (Optional) AREX-P03-002	Application Number 09/994,466
		Applicant Madiyalakan	FEB 27 2003
		Filing Date November 26, 2001	Group Art Unit 1614
<i>TECH CENTER 1600/2900</i>			

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	SEARCHED & TRAILED	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SSH		AA 5,506,343	4/9/96	Kufe			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

SSH	AB	Burchell, J. et al. Detection of the Tumour-Associated Antigens Recognized by the Monoclonal Antibodies HMFG-1 and 2 in Serum From Patients with Breast Cancer. Int. J. Cancer 34, 763-768 (1984).
SSH	AC	Burchell, J. et al. Active Specific Immunotherapy: PEM as a Potential Target Molecule. Cancer Surv. 18, 135-148 (1993).
SSH	AD	Codington, J.F. and Frim, D.M. "Cell-Surface Macromolecular and Morphological Changes Related to Allotransplantability in the TA3 Tumor" in Biomembranes, L.A. Mansoe, ed. Plenum Pub. Corp., N.Y. p. 207-259 (1983).
SSH	AE	Devine, P.L. and Mackenzie, I.F.C. Mucins: Structure, Function, and Associations with Malignancy. BioEssays 14, 619-625 (Sept. 1993).
SSH	AF	Gendler, S.J. et al. Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. PNAS 84, 6060-6064 (Sept. 1987).
SSH	AG	Gendler, S.J. et al. Molecular Cloning and Expression of Human Tumor-associated Polymorphic Epithelial Mucin. J. Biol. Chem. 265, 15286-15293 (5 Sept. 1990).
SSH	AH	Ho, S.B. et al. Heterogeneity of Mucin Gene Expression in Normal and Neoplastic Tissues. Cancer Res. 53, 641-651 (1 Feb. 1993).
SSH	AI	Hull, S.R. et al. Oligosaccharide Differences in the DF3 Sialomucin Antigen from Normal Human Milk and the BT-20 Human Breast Carcinoma Cell Line. Cancer Commun. 1, 261-267 (1989).
SSH	AJ	Jentoff, N. Why are proteins O-glycosylated? TIBS 15, 291-294 (Aug. 1990).
SSH	AK	Lightenberg, M.J.L. et al. Episialin, a Carcinoma-associated Mucin, is Generated by a Polymorphic Gene Encoding Splice Variants with Alternative Amino Termini. J. Biol. Chem. 265, 5573-5578 (5 April 1990).
SSH	AL	Linsley, P.S. et al. Elevated Levels of a High Molecular Weight Antigen Detected by Antibody W1 in Sera from Breast Cancer Patients. Cancer Res. 46, 5444-5450 (Oct. 1986).

9073963_1

all info

4/30/04

Form PTO/SB/08 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Docket Number (Optional) AREX-P03-002	Application Number 09/994,466
		Applicant Madiyalakan	
		Filing Date November 26, 2001	Group Art Unit 1614
<p><i>O P E J C</i> <i>STP 2/1/2003</i> <i>PTO/USPTO</i></p> <p>Magnani, J.L. et al. Identification of the Gastrointestinal and Pancreatic Cancer-associated Antigen Detected by Monoclonal Antibody 19-9 in the Sera of Patients as a Mucin. <i>Cancer Res.</i> 43, 5489-5492 (Nov. 1983).</p>			
<p><i>SPH</i></p> <p>Metzgar, R.S. et al. Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. <i>PNAS</i> 81, 5242-5246 (Aug. 1984).</p>			
<p><i>SPH</i></p> <p>AO Miller, S.C. et al. Ultrastructural and Histochemical Differences in Cell Surface Properties of Strain-Specific and Nonstrain-Specific TA3 Adenocarcinoma Cells. <i>J. Cell Biol.</i> 72, 511 (1977).</p>			
<p><i>SPH</i></p> <p>AP Neutra, M.R. and Forstner, J.F. "Gastrointestinal Mucus: Synthesis, Secretion, and Function" in <i>Physiology of the Gastrointestinal Tract</i>, 2nd edition, L.R. Johnson, cd. Raven Press, N.Y. p. 975-7009 (1987).</p>			
<p><i>SPH</i></p> <p>AQ Parry, G. et al. Determination of Apical Membrane Polarity in Mammary Epithelial Cell Cultures: The Role of Cell-Cell, Cell-Substratum, and Membrane-Cytoskeleton Interactions. <i>Exp. Cell Res.</i> 188, 302-311 (1990).</p>			
<p><i>SPH</i></p> <p>AR Pihl, E. et al. Mucinous Colorectal Carcinoma: Immunopathology and Prognosis. <i>Pathol.</i> 12, 439-437 (1980).</p>			
<p><i>SPH</i></p> <p>AS Regimbald, L.H. et al. The Breast Mucin MUC1 as a Novel Adhesion Ligand for Endothelial Intercellular Adhesion Molecule 1 in Breast Cancer. <i>Cancer Res.</i> 56, 4244-4249 (15 Sept. 1996).</p>			
<p><i>✓</i></p> <p>AT Rittenhouse, H.G. et al. Mucin-Type Glycoproteins as Tumor Markers. <i>Lab Med.</i> 16, 556-560 (Sept. 1985).</p>			
<p><i>✓</i></p> <p>AU Siddiqui, J. et al. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. <i>PNAS</i> 85, 2320-2323 (April 1988).</p>			
<p><i>✓</i></p> <p>AV Wong, R.C.K. et al. Signal Transduction via Leukocyte Antigen CD43 (Sialophorin): Feedback Regulation by Protein Kinase C1. <i>J. Immunol.</i> 144, 1455-1460 (15 Feb. 1990).</p>			
EXAMINER <i>Schwartz</i>		DATE CONSIDERED <i>1/30/04</i>	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

RECEIVED
FEB 27 2003
TECH CENTER 1600/2000